The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Biogen Inc. (NASDAQ:BIIB)’s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous ...

New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of ...

The Boston Business Journal reports that Biogen is trimming members of its multiple sclerosis team. The affected employees are eligible for severance and in some cases the chance to apply for ...

Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple ...

Biogen's fourth-quarter revenue from multiple sclerosis products fell 8% to $1.17 billion as some of the therapies face competition from cheaper generics. The company's once-blockbuster drug ...

Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the drug for ...

Biogen (NASDAQ:BIIB ... financials while its full-year outlook disappointed due to its underperforming multiple sclerosis franchise. “We believe 2024 was an important year on our journey ...

Biogen Inc.’s stock BIIB tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug ...

Octave Bioscience, Inc., a company offering treatment for multiple sclerosis and other neurodegenerative diseases, said it will conduct a real-world study with its sponsor Biogen (Nasdaq ...

Biogen's strategy has its roots in the 2003 merger of Biogen (multiple sclerosis drug Avonex) and Idec (cancer drug Rituxan). The firm expanded its neurology portfolio beyond MS, including the ...

can exceed the multiple sclerosis product decline," Viehbacher told analysts on a conference call. Biogen shares have lost more than 40% of their value in 2024 as sales of Alzheimer's disease drug ...